Sickle Cell Nephropathy Mortality in the United States, 1999-2024: Persistent Racial Inequity in the Disease-Modifying Therapy Era (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0284; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The disease-modifying therapy era—marked by expanded hydroxyurea uptake, L-glutamine approval (2017), crizanlizumab and voxelotor (2019), and gene therapy breakthroughs (2023) has raised expectations for improved organ outcomes. Conclusion SCN mortality has not meaningfully declined over 25 years despite the introduction of multiple disease-modifying therapies, and the Black–White mortality ratio exceeds 20-fold—among the starkest racial disparities documented in organ-specific mortality literature. The failure of therapeutic advances to reach population-level mortality benefit likely reflects access barriers, underdiagnosis of early nephropathy."
Gene Therapies • Genetic Disorders • Hematological Disorders • Renal Disease • Sickle Cell Disease
|
|
Naga Anvesh Kodali; Sukriti Seth; Chandan Mitra; Mahesh K. Vaghela
|